Brooklyn ImmunoTherapeutics, Inc.
Index- P/E- EPS (ttm)-2.10 Insider Own1.60% Shs Outstand58.80M Perf Week-0.40%
Market Cap14.59M Forward P/E- EPS next Y-0.53 Insider Trans0.00% Shs Float34.00M Perf Month-30.81%
Income-107.50M PEG- EPS next Q-0.14 Inst Own26.30% Short Float3.01% Perf Quarter-63.42%
Sales- P/S- EPS this Y6.50% Inst Trans-18.25% Short Ratio2.01 Perf Half Y-87.10%
Book/sh0.25 P/B1.00 EPS next Y0.00% ROA-323.00% Target Price3.00 Perf Year-97.22%
Cash/sh0.33 P/C0.75 EPS next 5Y20.00% ROE-609.10% 52W Range0.21 - 10.10 Perf YTD-94.00%
Dividend- P/FCF- EPS past 5Y1.60% ROI- 52W High-97.52% Beta4.69
Dividend %- Quick Ratio3.10 Sales past 5Y- Gross Margin- 52W Low19.14% ATR0.04
Employees10 Current Ratio3.10 Sales Q/Q- Oper. Margin- RSI (14)33.15 Volatility11.22% 14.26%
OptionableYes Debt/Eq0.00 EPS Q/Q75.60% Profit Margin- Rel Volume0.66 Prev Close0.24
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume508.42K Price0.25
Recom2.00 SMA20-13.19% SMA50-38.06% SMA200-82.91% Volume336,428 Change4.47%
Dec-29-21Initiated Cantor Fitzgerald Overweight $9
Oct-06-21Initiated Maxim Group Buy $20
Jul-26-22 09:49AM
Jun-17-22 05:00PM
Jun-07-22 07:30AM
May-31-22 07:30AM
04:30PM Loading…
May-27-22 04:30PM
May-19-22 08:23AM
Apr-21-22 07:30AM
Apr-15-22 04:15PM
Mar-09-22 04:15PM
Mar-07-22 08:00AM
Jan-27-22 05:38PM
Jan-20-22 07:30AM
Jan-13-22 08:30AM
Dec-17-21 08:00AM
08:47AM Loading…
Dec-14-21 08:47AM
Dec-02-21 08:00AM
Nov-29-21 08:00AM
Nov-19-21 06:00AM
Nov-09-21 04:35PM
Oct-27-21 07:05AM
Oct-14-21 04:15PM
Oct-07-21 10:11PM
Sep-23-21 04:30PM
Sep-22-21 10:07AM
Sep-21-21 08:30AM
Sep-15-21 08:15AM
Sep-13-21 08:00AM
Sep-09-21 08:30AM
Aug-20-21 04:15PM
08:30AM Loading…
Aug-16-21 04:15PM
Aug-13-21 02:22PM
Jul-23-21 04:30PM
Jul-19-21 08:00AM
Jul-13-21 08:15AM
Jul-12-21 08:15AM
Jul-08-21 11:20AM
Jul-06-21 05:57PM
Jun-14-21 07:30AM
Jun-09-21 07:30AM
Jun-08-21 07:30AM
Jun-02-21 08:00AM
May-26-21 02:03PM
May-24-21 02:58PM
May-21-21 07:30AM
May-18-21 07:30AM
May-11-21 07:30AM
May-07-21 07:30AM
Apr-29-21 07:30AM
Apr-26-21 07:30AM
Apr-19-21 04:10PM
Apr-15-21 04:10PM
Apr-06-21 08:00AM
Mar-25-21 05:20PM
Dec-14-20 08:44AM
Nov-04-20 06:05PM
May-08-20 10:37PM
Brooklyn ImmunoTherapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing therapies to treat patients with cancer. Its advanced program is IRX-2 that is in a Phase 2b clinical trial in patients with squamous cell cancer of the head and neck. The company also develops therapies using gene-editing and cell therapy technology for the treatment of oncology, blood disorder, and monogenic disease. Brooklyn ImmunoTherapeutics, Inc. is based in Brooklyn, New York.